SG11201602679VA - Stable polypeptides binding to human complement c5 - Google Patents
Stable polypeptides binding to human complement c5Info
- Publication number
- SG11201602679VA SG11201602679VA SG11201602679VA SG11201602679VA SG11201602679VA SG 11201602679V A SG11201602679V A SG 11201602679VA SG 11201602679V A SG11201602679V A SG 11201602679VA SG 11201602679V A SG11201602679V A SG 11201602679VA SG 11201602679V A SG11201602679V A SG 11201602679VA
- Authority
- SG
- Singapore
- Prior art keywords
- human complement
- polypeptides binding
- stable polypeptides
- stable
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1350986 | 2013-08-28 | ||
PCT/EP2014/068282 WO2015028558A1 (en) | 2013-08-28 | 2014-08-28 | Stable polypeptides binding to human complement c5 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201602679VA true SG11201602679VA (en) | 2016-05-30 |
Family
ID=51539238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201602679VA SG11201602679VA (en) | 2013-08-28 | 2014-08-28 | Stable polypeptides binding to human complement c5 |
Country Status (29)
Country | Link |
---|---|
US (1) | US9994626B2 (en) |
EP (2) | EP3038633B1 (en) |
JP (2) | JP6767865B2 (en) |
KR (1) | KR102446636B1 (en) |
CN (1) | CN105658228B (en) |
AU (1) | AU2014314222B2 (en) |
BR (2) | BR112016003142A2 (en) |
CA (1) | CA2926976C (en) |
CY (1) | CY1123732T1 (en) |
DK (1) | DK3038633T3 (en) |
ES (1) | ES2842105T3 (en) |
HK (1) | HK1225656A1 (en) |
HR (1) | HRP20210013T1 (en) |
HU (1) | HUE052613T2 (en) |
IL (1) | IL244218A (en) |
LT (1) | LT3038633T (en) |
MX (1) | MX2016002397A (en) |
MY (1) | MY173804A (en) |
NZ (1) | NZ718153A (en) |
PH (1) | PH12016500371A1 (en) |
PL (1) | PL3038633T3 (en) |
PT (1) | PT3038633T (en) |
RS (1) | RS61347B1 (en) |
RU (2) | RU2020128977A (en) |
SA (1) | SA516370622B1 (en) |
SG (1) | SG11201602679VA (en) |
SI (1) | SI3038633T1 (en) |
UA (1) | UA117933C2 (en) |
WO (1) | WO2015028558A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201404942UA (en) | 2012-02-20 | 2014-09-26 | Swedish Orphan Biovitrum Ab Publ | Polypeptides binding to human complement c5 |
SG11201602679VA (en) * | 2013-08-28 | 2016-05-30 | Swedish Orphan Biovitrum Ab Publ | Stable polypeptides binding to human complement c5 |
RU2714156C2 (en) * | 2013-08-28 | 2020-02-12 | Аффибоди Аб | C5-binding polypeptides |
UY37651A (en) * | 2017-03-31 | 2018-10-31 | Swedish Orphan Biovitrum Ab Publ | IL-1R-I UNION POLYPEPTIDE |
CN117327188A (en) | 2017-07-11 | 2024-01-02 | 亚力兄制药公司 | Polypeptide binding complement component C5 or serum albumin and fusion protein thereof |
WO2023077139A1 (en) * | 2021-11-01 | 2023-05-04 | Ipc Research, Llc | Administration of c5-binding proteins |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE509359C2 (en) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Use of stabilized protein or peptide conjugates for the preparation of a drug |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
DK1325033T3 (en) | 2000-10-10 | 2010-04-06 | Genentech Inc | Inhibition of complement C5 activation for the treatment and prevention of delayed xenographic or acute vascular rejection |
AT410798B (en) * | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | METHOD FOR IDENTIFYING, ISOLATING AND PRODUCING ANTIGENS AGAINST A SPECIFIC PATHOGEN |
AU2002331601B2 (en) | 2001-08-17 | 2006-04-13 | Tanox, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b |
ITMI20021527A1 (en) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | C5 COMPONENT ANTIBODIES OF COMPLEMENT AND THEIR USE |
US7348401B2 (en) * | 2003-09-10 | 2008-03-25 | Innate Biotech, Inc. | Peptides that inhibit complement activation |
SE0400274D0 (en) * | 2004-02-09 | 2004-02-09 | Affibody Ab | New polypeptide |
GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
RU2477137C2 (en) * | 2006-03-08 | 2013-03-10 | АРКЕМИКС Эл Эл Си | Complement-binding aptamers and c5 agents applicable for treating ocular disorders |
PT2359834T (en) | 2006-03-15 | 2016-12-23 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
WO2009016043A2 (en) | 2007-07-31 | 2009-02-05 | Affibody Ab | New albumin binding compositions, methods and uses |
EP2231860B1 (en) | 2007-12-19 | 2011-10-05 | Affibody AB | Polypeptide derived from protein a and able to bind pdgf |
US9187535B2 (en) | 2007-12-19 | 2015-11-17 | Affibody Ab | Polypeptide derived from protein A and able to bind PDGF |
EP2072525A1 (en) | 2007-12-21 | 2009-06-24 | Affibody AB | New polypeptides having affinity for HER2 |
EP2815766B1 (en) | 2008-08-05 | 2017-07-05 | Novartis AG | Compositions and methods for antibodies targeting complement protein C5 |
EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
MX2013000314A (en) * | 2010-07-09 | 2013-01-29 | Affibody Ab | Polypeptides. |
SG11201404942UA (en) * | 2012-02-20 | 2014-09-26 | Swedish Orphan Biovitrum Ab Publ | Polypeptides binding to human complement c5 |
JP5980104B2 (en) | 2012-11-22 | 2016-08-31 | 三菱電機株式会社 | Liquid crystal display device manufacturing method and liquid crystal display device manufacturing system |
WO2014096163A1 (en) | 2012-12-19 | 2014-06-26 | Affibody Ab | New polypeptides |
SG11201602679VA (en) * | 2013-08-28 | 2016-05-30 | Swedish Orphan Biovitrum Ab Publ | Stable polypeptides binding to human complement c5 |
RU2714156C2 (en) * | 2013-08-28 | 2020-02-12 | Аффибоди Аб | C5-binding polypeptides |
-
2014
- 2014-08-28 SG SG11201602679VA patent/SG11201602679VA/en unknown
- 2014-08-28 KR KR1020167007498A patent/KR102446636B1/en active IP Right Grant
- 2014-08-28 UA UAA201603124A patent/UA117933C2/en unknown
- 2014-08-28 CN CN201480057470.XA patent/CN105658228B/en active Active
- 2014-08-28 AU AU2014314222A patent/AU2014314222B2/en active Active
- 2014-08-28 MY MYPI2016700583A patent/MY173804A/en unknown
- 2014-08-28 RU RU2020128977A patent/RU2020128977A/en unknown
- 2014-08-28 JP JP2016537298A patent/JP6767865B2/en active Active
- 2014-08-28 LT LTEP14765883.5T patent/LT3038633T/en unknown
- 2014-08-28 SI SI201431739T patent/SI3038633T1/en unknown
- 2014-08-28 MX MX2016002397A patent/MX2016002397A/en unknown
- 2014-08-28 BR BR112016003142A patent/BR112016003142A2/en not_active Application Discontinuation
- 2014-08-28 CA CA2926976A patent/CA2926976C/en active Active
- 2014-08-28 WO PCT/EP2014/068282 patent/WO2015028558A1/en active Application Filing
- 2014-08-28 RU RU2016111115A patent/RU2733897C2/en active
- 2014-08-28 EP EP14765883.5A patent/EP3038633B1/en active Active
- 2014-08-28 NZ NZ718153A patent/NZ718153A/en unknown
- 2014-08-28 BR BR122023020080-2A patent/BR122023020080A2/en unknown
- 2014-08-28 ES ES14765883T patent/ES2842105T3/en active Active
- 2014-08-28 PL PL14765883T patent/PL3038633T3/en unknown
- 2014-08-28 US US14/914,290 patent/US9994626B2/en active Active
- 2014-08-28 EP EP20201264.7A patent/EP3811961A1/en active Pending
- 2014-08-28 DK DK14765883.5T patent/DK3038633T3/en active
- 2014-08-28 HU HUE14765883A patent/HUE052613T2/en unknown
- 2014-08-28 PT PT147658835T patent/PT3038633T/en unknown
- 2014-08-28 RS RS20210005A patent/RS61347B1/en unknown
-
2016
- 2016-02-22 IL IL244218A patent/IL244218A/en active IP Right Grant
- 2016-02-24 PH PH12016500371A patent/PH12016500371A1/en unknown
- 2016-02-25 SA SA516370622A patent/SA516370622B1/en unknown
- 2016-12-14 HK HK16114209A patent/HK1225656A1/en unknown
-
2020
- 2020-07-01 JP JP2020113725A patent/JP2020172505A/en active Pending
- 2020-12-30 CY CY20201101229T patent/CY1123732T1/en unknown
-
2021
- 2021-01-04 HR HRP20210013TT patent/HRP20210013T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267724B (en) | Polypeptides binding to human complement c5 | |
IL275376A (en) | Hyperglycosylated binding polypeptides | |
IL240838A0 (en) | Anti-lag-3 binding proteins | |
HK1225656A1 (en) | Stable polypeptides binding to human complement c5 | |
HK1218920A1 (en) | Improved tnf binding proteins tnf | |
ZA201507808B (en) | Binding element | |
ZA201600535B (en) | Cosmetic composition | |
SG11201508627XA (en) | Peptides binding to parallel-stranded g-quadruplexes | |
GB201303977D0 (en) | Binding polypeptides | |
GB201318147D0 (en) | Herbal composition | |
GB201318146D0 (en) | Herbal composition | |
GB201310949D0 (en) | Binding Motif |